TRCT
TTRX

Tower Research Capital (TRC)’s Turn Therapeutics TTRX Stock Holding History

Tower Research Capital (TRC)’s Portfolio TTRX Stock Details TTRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-137
Closed -$540 – 5749
2025
Q4 		$540 Buy
+137
New +$571 ﹤0.01% 4876

Other funds holding TTRX

DI
DDFG Inc Thousand Oaks, California $464M AUM 16.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WSC
Wellington Shields & Co New York $392M AUM 30.65% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
BBHC
Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
RW
RVW Wealth Los Angeles, California $1.52B AUM 23.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tower Research Capital (TRC)'s TTRX Position: Q1 2026 in Review

Tower Research Capital (TRC) sold out of Turn Therapeutics (TTRX) in Q1 2026, closing a stake of 137 shares — an estimated $540 sold.

Tower Research Capital (TRC) first reported a position in TTRX in Q4 2025 and held it in 1 quarter. The position peaked at $540 in Q4 2025. 20 funds tracked by Wall St. Rank hold TTRX as of Q1 2026.

  • Tower Research Capital (TRC) reported no remaining Turn Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 137 Turn Therapeutics shares in Q1 2026, an estimated $540.
  • Tower Research Capital (TRC) first reported a position in Turn Therapeutics in Q4 2025 and held it in 1 quarter.
  • Tower Research Capital (TRC)'s Turn Therapeutics position peaked at $540 in Q4 2025.
  • 20 funds tracked by Wall St. Rank held Turn Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.